Cocrystal Pharma reports 2025 net loss of $8.8M ($0.78/sh); cash $7.7M; norovirus challenge study underway

Cocrystal Pharma, Inc.

Net loss $8.8M ($0.78/sh) vs $17.5M ($1.72/sh) in 2024; R&D spend down to $5.1M from $12.5M.
Unrestricted cash $7.7M at Dec 31, 2025 vs $9.9M a year earlier; working capital $5.9M.
Phase 1b norovirus challenge study of CDI-988 underway at Emory; first cohort evaluating GII.2 strain.
CDI-988 is first oral antiviral candidate for norovirus; no approved treatments/vaccines exist; $60B global burden.
Influenza CC-42344 Phase 2a completed; efficacy not reported due to trial conduct; plans for additional Phase 2a study.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Cocrystal Pharma, Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the year ended December 31, 2025

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Cocrystal Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.